Topical SB-275833 Ointment, 1% For The Treatment Of Impetigo

• Status: Completed
• Trial end date: 2005-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this study is to determine if topical SB-275833 ointment, 1% is as safe and effective as topical sodium fusidate ointment, 2% for the treatment of impetigo in adults and children as young as 9 months of age.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Retapamulin

Criteria

Inclusion criteria:

• Must have primary impetigo with total lesion area being 100 square centimeters or less.

• Women who could bear children must have a negative urine pregnancy test and agree to either abstain from sexual intercourse or the use of specific effective contraceptive measures.

Exclusion Criteria:

• Any signs and symptoms of systemic infection.

• Any serious underlying disease that could be imminently life threatening.